BIRC3 and ovarian cancer: In support of an antitumor tumor immune response, by targeting intracellular PD-L1 with a cell-penetrating antibody, the mRNA expression of PDCD1LG2, BIRC3, RELB, and VSIR was significantly decreased in ovarian cancer cells (Figure S4B).